| D |
2026-04-08 16:45 |
2026-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
Chief STRATEGY Off |
M - OptEx |
— |
+2,726 |
24.0K |
+13% |
— |
| D |
2026-04-08 16:45 |
2026-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
Chief STRATEGY Off |
F - Tax |
$48.94 |
-846 |
23.1K |
-4% |
-$41.4K |
| D |
2026-04-03 16:41 |
2026-01-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
Chief STRATEGY Off |
A - Grant |
$24.16 |
+365 |
17.0K |
+2% |
+$8,818 |
| D |
2026-04-03 16:41 |
2026-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
Chief STRATEGY Off |
M - OptEx |
— |
+5,975 |
23.0K |
+35% |
— |
| D |
2026-04-03 16:41 |
2026-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
Chief STRATEGY Off |
F - Tax |
$48.13 |
-1,756 |
21.2K |
-8% |
-$84.5K |
| D |
2025-12-17 |
2025-12-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,000 |
28.7K |
+26% |
+$53.0K |
| D |
2025-12-17 |
2025-12-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$41.56 |
-12.0K |
16.7K |
-42% |
-$500.7K |
| D |
2025-12-01 |
2025-11-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$42.89 |
-200 |
22.7K |
-0.9% |
-$8,578 |
| D |
2025-12-01 |
2025-11-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$22.89 |
+200 |
22.9K |
+0.9% |
+$4,578 |
| DM |
2025-11-19 |
2025-11-17 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$41.24 |
-12.5K |
22.7K |
-35% |
-$514.2K |
| D |
2025-11-19 |
2025-11-17 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
35.2K |
+23% |
+$57.4K |
| DM |
2025-10-16 |
2025-10-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$37.67 |
-12.4K |
28.7K |
-30% |
-$465.8K |
| D |
2025-10-16 |
2025-10-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
41.1K |
+19% |
+$57.4K |
| D |
2025-10-01 |
2025-09-29 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$38.33 |
-42.0K |
34.6K |
-55% |
-$1.61M |
| D |
2025-10-01 |
2025-09-29 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$17.92 |
+42.0K |
76.6K |
+122% |
+$752.6K |
| DM |
2025-09-17 |
2025-09-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$36.46 |
-16.4K |
34.6K |
-32% |
-$598.0K |
| D |
2025-09-17 |
2025-09-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
51.0K |
+15% |
+$57.4K |
| DM |
2025-09-08 |
2025-09-04+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$15.51 |
+98.7K |
57.8K |
New |
+$1.53M |
| DM |
2025-09-08 |
2025-09-04+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$35.54 |
-98.7K |
44.5K |
-69% |
-$3.51M |
| DM |
2025-09-03 |
2025-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$33.68 |
-3,972 |
43.4K |
-8% |
-$133.8K |
| DM |
2025-09-03 |
2025-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$15.50 |
+23.3K |
43.7K |
+114% |
+$361.2K |
| D |
2025-09-03 |
2025-09-03 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$35.50 |
-15.1K |
44.5K |
-25% |
-$535.7K |
| D |
2025-08-20 |
2025-08-18 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
56.4K |
+13% |
+$57.4K |
| DM |
2025-08-20 |
2025-08-18 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$33.77 |
-16.2K |
40.2K |
-29% |
-$547.1K |
| DM |
2025-08-07 |
2025-08-05 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$11.44 |
+138.6K |
177.9K |
+353% |
+$1.59M |
| DM |
2025-08-07 |
2025-08-05 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$33.20 |
-138.6K |
49.9K |
-74% |
-$4.60M |
| D |
2025-08-07 |
2025-07-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
A - Grant |
$15.63 |
+752 |
49.9K |
+2% |
+$11.8K |
| D |
2025-07-16 |
2025-07-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$28.72 |
-18.9K |
49.2K |
-28% |
-$542.8K |
| D |
2025-07-16 |
2025-07-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
68.1K |
+11% |
+$57.4K |
| D |
2025-06-18 |
2025-06-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$28.28 |
-17.3K |
61.6K |
-22% |
-$489.2K |
| D |
2025-06-18 |
2025-06-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$8.83 |
+6,500 |
78.9K |
+9% |
+$57.4K |
| DM |
2025-06-11 |
2025-06-09+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$30.48 |
-70.9K |
72.4K |
-49% |
-$2.16M |
| DM |
2025-06-11 |
2025-06-09+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$10.36 |
+70.9K |
82.7K |
+600% |
+$734.2K |
| D |
2025-05-21 |
2025-05-19 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$26.41 |
-12.0K |
72.4K |
-14% |
-$316.9K |
| D |
2025-05-21 |
2025-05-19 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$3.80 |
+7,000 |
84.4K |
+9% |
+$26.6K |
| D |
2025-04-16 |
2025-04-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$3.80 |
+7,000 |
89.4K |
+8% |
+$26.6K |
| DM |
2025-04-16 |
2025-04-14 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$20.48 |
-12.0K |
77.4K |
-13% |
-$245.8K |
| D |
2025-04-09 |
2025-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+2,726 |
83.2K |
+3% |
— |
| D |
2025-04-09 |
2025-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$20.28 |
-801 |
82.4K |
-1.0% |
-$16.2K |
| DM |
2025-04-03 |
2025-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+3,519 |
79.7K |
+5% |
— |
| DM |
2025-04-03 |
2025-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$21.77 |
-1,034 |
81.0K |
-1% |
-$22.5K |
| D |
2025-03-19 |
2025-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$22.61 |
-577 |
78.0K |
-0.7% |
-$13.0K |
| D |
2025-03-19 |
2025-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+1,964 |
78.5K |
+3% |
— |
| D |
2025-03-12 |
2025-03-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$21.06 |
-12.4K |
76.6K |
-14% |
-$261.3K |
| D |
2025-03-12 |
2025-03-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$3.80 |
+7,000 |
89.0K |
+9% |
+$26.6K |
| D |
2025-02-12 |
2025-02-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$3.80 |
+7,000 |
96.0K |
+8% |
+$26.6K |
| D |
2025-02-12 |
2025-02-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$19.57 |
-14.0K |
82.0K |
-15% |
-$274.0K |
| DM |
2025-01-15 |
2025-01-13 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$18.24 |
-14.0K |
90.7K |
-13% |
-$255.4K |
| D |
2025-01-15 |
2025-01-13 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$3.80 |
+7,000 |
103.0K |
+7% |
+$26.6K |
| D |
2024-12-18 |
2024-12-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+16.0K |
119.0K |
+16% |
+$25.5K |
| D |
2024-12-18 |
2024-12-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$20.44 |
-23.0K |
96.0K |
-19% |
-$470.5K |
| D |
2024-11-20 |
2024-11-18 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$21.04 |
-17.0K |
103.0K |
-14% |
-$357.7K |
| D |
2024-11-20 |
2024-11-18 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+10.0K |
120.0K |
+9% |
+$15.9K |
| D |
2024-10-17 |
2024-10-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$26.87 |
-17.0K |
110.0K |
-13% |
-$456.8K |
| D |
2024-10-17 |
2024-10-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+10.0K |
127.0K |
+9% |
+$15.9K |
| D |
2024-09-25 |
2024-09-23 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$24.99 |
-17.5K |
117.0K |
-13% |
-$437.3K |
| D |
2024-09-25 |
2024-09-23 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+10.0K |
134.5K |
+8% |
+$15.9K |
| DM |
2024-09-04 |
2024-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$26.74 |
-1,899 |
123.1K |
-2% |
-$50.8K |
| DM |
2024-09-04 |
2024-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$0.00 |
+6,463 |
125.1K |
+5% |
$0 |
| D |
2024-08-29 |
2024-08-27 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$26.91 |
-17.5K |
119.9K |
-13% |
-$470.9K |
| D |
2024-08-29 |
2024-08-27 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+10.0K |
137.4K |
+8% |
+$15.9K |
| D |
2024-04-08 |
2024-04-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+2,726 |
126.8K |
+2% |
— |
| D |
2024-04-08 |
2024-04-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$17.90 |
-801 |
126.0K |
-0.6% |
-$14.3K |
| D |
2024-04-03 |
2024-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+1,773 |
124.6K |
+1% |
— |
| D |
2024-04-03 |
2024-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$19.70 |
-521 |
124.1K |
-0.4% |
-$10.3K |
| D |
2024-03-05 |
2024-03-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
S - Sale+OE |
$22.03 |
-1,189 |
122.8K |
-1.0% |
-$26.2K |
| D |
2024-03-05 |
2024-03-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
$1.59 |
+656 |
124.0K |
+0.5% |
+$1,043 |
| DM |
2023-09-06 |
2023-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+4,691 |
122.8K |
+4% |
— |
| DM |
2023-09-06 |
2023-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$17.76 |
-1,378 |
122.0K |
-1% |
-$24.5K |
| D |
2023-04-11 |
2023-04-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$10.71 |
-801 |
120.1K |
-0.7% |
-$8,579 |
| D |
2023-04-11 |
2023-04-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+2,727 |
120.9K |
+2% |
— |
| DM |
2023-03-20 |
2023-03-16+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+4,946 |
119.0K |
+4% |
— |
| DM |
2023-03-20 |
2023-03-16+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$11.26 |
-1,453 |
116.0K |
-1% |
-$16.4K |
| D |
2022-09-06 |
2022-07-15 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
A - Grant |
$9.56 |
+1,048 |
113.3K |
+0.9% |
+$10.0K |
| D |
2022-09-06 |
2022-09-02 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$11.44 |
-577 |
114.6K |
-0.5% |
-$6,601 |
| D |
2022-09-06 |
2022-09-02 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+1,964 |
115.2K |
+2% |
— |
| D |
2022-03-23 |
2022-03-21 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$10.98 |
-1,461 |
112.2K |
-1% |
-$16.0K |
| D |
2022-03-23 |
2022-03-21 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+4,611 |
113.7K |
+4% |
— |
| D |
2022-03-18 |
2022-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
F - Tax |
$10.13 |
-681 |
109.1K |
-0.6% |
-$6,899 |
| D |
2022-03-18 |
2022-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
M - OptEx |
— |
+1,964 |
109.7K |
+2% |
— |
| DM |
2022-03-18 |
2021-07-15+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Tessari Eben |
COO |
A - Grant |
$10.51 |
+1,838 |
106.8K |
+2% |
+$19.3K |